

Supporting Information

Divergent Construction of 3-(Indol-2-yl)succinimide/maleimide and Fused Benzodiazepine Skeletons from 2-(1*H*-Indol-1-yl)anilines and Maleimides

Chunhua Ma, Yue Wang, Guang Chen, Jingyi Li, Yuqin Jiang, Xinying Zhang* and Xuesen Fan*

NMPA Key Laboratory for Research and Evaluation of Innovative Drug, Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, School of Chemistry and Chemical Engineering, Henan Normal University,

Xinxiang, Henan 453007, China

E-mail: xinyingzhang@htu.cn; xuesen.fan@htu.cn

Table of Contents

I	General experimental information	S3
II	Experimental procedures and spectroscopic data	S4-S25
III	Mechanism studies	S26-S28
IV	Cell antiproliferative activity assay	S29
V	NMR spectra of 3a-3v	S30-S56
VI	NMR spectra of 4a-4y	S57-S87
VII	NMR spectra of 5a-5f	S88-S94
VIII	X-ray crystal structure and data of 3a	S95-S96
IX	X-ray crystal structure and data of 4a	S97-S98
X	References	S99

I. General experimental information

Unless otherwise noted, all reagents including catalyst $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ were purchased from commercial sources and used without further purification. 2-(1*H*-Indol-1-yl)anilines (**1**) were prepared based on literature procedures.¹ Melting points were recorded with a micro melting point apparatus and uncorrected. The ^1H NMR spectra were recorded at 400 MHz or 600 MHz. The ^{13}C NMR spectra were recorded at 100 MHz or 150 MHz. The ^{19}F NMR spectra were recorded at 376 MHz or 565 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), dd (doublet of doublets), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. High resolution mass spectra (HRMS) were obtained *via* ESI mode by using a MicroTOF mass spectrometer. All reactions were monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data

1. Typical procedure for the synthesis of **3a** and spectroscopic data of **3a-3v**

To a reaction tube equipped with a stir bar were added 2-(1*H*-indol-1-yl)aniline (**1a**, 41.6 mg, 0.2 mmol), EA (2 mL), *N*-methylmaleimide (**2a**, 33.3 mg, 0.3 mmol), [Ru(*p*-cymene)Cl₂]₂ (6.12 mg, 0.01 mmol), AgSbF₆ (13.7 mg, 0.04 mmol) and AcOH (57 μL, 1.0 mmol) with stirring. The mixture was stirred at 80 °C under air for 12 h. Upon completion, it was cooled to room temperature, quenched with saturated aqueous solution of NaHCO₃ (1 mL), filtered through a pad of celite, and extracted with CH₂Cl₂ (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (4:1) as eluent to afford **3a**. **3b-3v** were obtained in a similar manner except for that the reaction for the synthesis of **3v** was carried out at 60 °C.

3-(1-(2-Aminophenyl)-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3a)

Eluent: petroleum ether/ethyl acetate (4:1). Yellow solid (43.4 mg, 68%, dr = 0.6:0.4), mp 90.2-92.1 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.62-7.60 (m, 1H), 7.30-7.27 (m, 1.4H), 7.15-7.13 (m, 2H), 7.02 (d, *J* = 7.8 Hz, 0.6H), 6.96-6.94 (m, 1H), 6.88-6.80 (m, 2H), 6.57 (s, 0.6H), 6.56 (s, 0.4H), 4.13-4.08 (m, 1H), 3.54 (br s, 2H), 2.96-2.83 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.8, 176.0, 175.7, 175.6, 144.8, 144.5, 138.0, 137.6, 136.0, 135.9, 130.6, 130.5, 130.4, 130.3, 127.7, 127.6, 122.7, 121.8, 121.7, 120.9, 120.8, 120.7, 120.6, 119.0, 118.7, 116.7, 116.3, 110.5, 110.4, 102.4, 101.7, 39.2, 39.0, 36.4, 35.9, 25.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₇N₃O₂Na 342.1213; Found 342.1207.

3-(1-(2-Aminophenyl)-6-methyl-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3b)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (40.0 mg, 60%, dr = 0.55:0.45), mp 180.8-181.9 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.48 (d, *J* = 7.8 Hz, 1H), 7.30-7.26 (m, 1.55H), 7.02 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 0.45H), 6.98 (d, *J* = 7.8 Hz, 1H), 6.89-6.81 (m, 2H), 6.74 (s, 0.55H), 6.73 (s, 0.45H), 6.52 (s, 0.45H), 6.51 (s, 0.55H), 4.11-4.06 (m, 1H), 3.70 (s, 0.9H), 3.41 (s, 1.1H), 2.95-2.83 (m, 5H), 2.38 (s, 3H). ¹³C{¹H} NMR (150

MHz, CDCl₃): δ 176.9, 176.0, 175.8, 175.7, 144.9, 144.6, 138.4, 138.0, 135.2, 135.1, 132.7, 130.6, 130.5, 130.4, 130.3, 125.5, 125.4, 122.6, 122.5, 122.0, 121.9, 120.4, 120.3, 118.9, 118.6, 116.6, 116.2, 110.3, 110.2, 102.2, 101.6, 39.2, 39.0, 36.4, 35.9, 25.1, 21.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₀H₂₀N₃O₂ 334.1550; Found 334.1543.

3-(1-(2-Aminophenyl)-6-methoxy-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3c)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (39.8 mg, 57%, dr = 0.6:0.4), mp 200.1-202.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.47 (d, *J* = 9.0 Hz, 1H), 7.31-7.27 (m, 1.6H), 7.03 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 0.4H), 6.89-6.80 (m, 3H), 6.50 (s, 0.4H), 6.49 (s, 0.6H), 6.40 (d, *J* = 1.8 Hz, 0.6H), 6.39 (d, *J* = 1.8 Hz, 0.4H), 4.10-4.05 (m, 1H), 3.733 (s, 1.8H), 3.729 (s, 1.2H), 3.71 (s, 0.8H), 3.43 (s, 1.2H), 2.95-2.82 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 176.1, 175.8, 175.7, 157.1, 144.8, 144.5, 138.8, 138.4, 134.6, 134.5, 130.6, 130.5, 130.4, 130.3, 121.8, 121.7, 121.4, 121.3, 119.0, 118.7, 116.7, 116.3, 110.8, 110.7, 102.3, 101.7, 93.8, 93.7, 55.7, 39.3, 39.0, 36.4, 35.9, 25.1. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₀H₁₉N₃O₃Na 372.1319; Found 372.1309.

3-(1-(2-Aminophenyl)-6-fluoro-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3d)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (43.8 mg, 65%, dr = 0.5:0.5), mp 215.0-216.2 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.52-7.50 (m, 1H), 7.30-7.27 (m, 1.5H), 7.02-7.01 (m, 0.5H), 6.92-6.81 (m, 3H), 6.65-6.62 (m, 1H), 6.55 (s, 0.5H), 6.54 (s, 0.5H), 4.12-4.07 (m, 1H), 3.71 (s, 1H), 3.41 (s, 1H), 2.97-2.83 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.7, 175.9, 175.6, 175.5, 160.3 (d, ¹*J*_{C-F} = 237.0 Hz), 144.7, 144.4, 138.1 (d, ³*J*_{C-F} = 11.9 Hz), 137.7 (d, ³*J*_{C-F} = 12.0 Hz), 136.4 (d, ⁴*J*_{C-F} = 2.3 Hz), 136.3 (d, ⁴*J*_{C-F} = 2.7 Hz), 130.8, 130.7, 130.4, 130.1, 124.1, 124.0, 121.6 (d, ³*J*_{C-F} = 9.9 Hz), 121.5, 121.48 (d, ³*J*_{C-F} = 9.9 Hz), 121.4, 119.1, 118.8, 116.8, 116.4, 109.6 (d, ²*J*_{C-F} = 25.8 Hz), 109.5 (d, ²*J*_{C-F} = 23.4 Hz), 102.4, 101.8, 97.0 (d, ²*J*_{C-F} = 27.2 Hz), 96.9 (d, ²*J*_{C-F} = 26.1 Hz), 39.2, 39.0, 36.3, 35.8, 25.1. ¹⁹F NMR (565 MHz, CDCl₃): δ -119.39 – -119.43 (m). HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆FN₃O₂Na 360.1119; Found 360.1119.

3-(1-(2-Aminophenyl)-6-chloro-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3e)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (45.2 mg, 64%, dr = 0.55:0.45), mp 220.0-221.7 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.50 (d, *J* = 8.4 Hz, 1H), 7.31-7.27 (m, 1.55H), 7.11-7.10 (m, 1H), 7.00 (d, *J* = 6.6 Hz, 0.45H), 6.94 (s, 0.55H), 6.93 (s, 0.45H), 6.88-6.81 (m, 2H), 6.55 (s, 0.45H), 6.54 (s, 0.55H), 4.11-4.06 (m, 1H), 3.70 (s, 0.9H), 3.41 (s, 1.1H), 2.96-2.82 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.6, 175.7, 175.5, 175.4, 144.7, 144.4, 138.4, 138.0, 136.8, 136.7, 130.9, 130.8, 130.4, 130.2, 128.7, 126.2, 126.1, 121.6, 121.59, 121.56, 121.1, 119.1, 118.8, 116.9, 116.4, 110.45, 110.41, 102.4, 101.7, 39.2, 38.9, 36.2, 35.7, 25.2. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆ClN₃O₂Na 376.0823; Found 376.0814.

3-(1-(2-Aminophenyl)-6-bromo-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3f)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (48.4 mg, 61%, dr = 0.6:0.4), mp 236.1-236.7 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.56-7.53 (m, 1H), 7.27-7.16 (m, 2.6H), 6.93-6.89 (m, 1.4H), 6.83-6.81 (m, 1H), 6.72-6.63 (m, 2H), 4.93 (s, 1.2H), 4.77 (s, 0.8H), 4.28 (dd, *J*₁ = 9.6 Hz, *J*₂ = 5.2 Hz, 0.6H), 4.08-4.04 (m, 0.4H), 2.95-2.84 (m, 2H), 2.81 (s, 1.2H), 2.70 (s, 1.8H). ¹³C{¹H} NMR (100 MHz, DMSO): δ 177.3, 176.6, 176.4, 176.0, 146.3, 139.2, 139.0, 138.4, 138.3, 130.8, 130.6, 130.5, 130.4, 127.1, 126.9, 123.4, 122.5, 120.0, 119.9, 117.0, 116.9, 116.6, 116.4, 115.0, 114.8, 113.1, 112.9, 103.8, 101.2, 38.9, 36.5, 35.0, 25.2, 25.0. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆BrN₃O₂Na 420.0318; Found 420.0295.

3-(1-(2-Aminophenyl)-6-(trifluoromethyl)-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3g)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (57.3 mg, 74%, dr = 0.7:0.3), mp 82.7-84.6 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.68 (d, *J* = 8.4 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 1H), 7.32-7.28 (m, 1.7H), 7.22 (s, 0.7H), 7.21 (s, 0.3H), 7.02-7.01 (m, 0.3H), 6.90-6.82 (m, 2H), 6.63 (s, 0.3H), 6.62 (s, 0.7H), 4.14 (dd, *J*₁ = 9.6 Hz, *J*₂ = 5.4 Hz, 0.3H), 4.10 (dd, *J*₁ = 9.6 Hz, *J*₂ = 5.4 Hz, 0.7H), 3.72 (br s, 0.6H), 3.42 (br s, 1.4H), 2.97-2.83 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.4, 175.6, 175.4, 175.3, 144.7, 144.4, 139.0, 138.9, 136.9, 136.5, 131.1, 131.0, 130.4, 130.2, 130.1, 130.0, 125.0 (q, ¹*J*_{C-F} = 270.3 Hz), 124.8 (q, ²*J*_{C-F} = 31.8 Hz), 121.2, 121.1, 120.8,

120.7, 119.2, 118.9, 117.5 (q, $^3J_{C-F} = 3.6$ Hz), 117.0, 116.5, 108.0 (q, $^3J_{C-F} = 4.4$ Hz), 102.5, 101.8, 39.2, 38.9, 36.2, 35.7, 25.18, 25.16. ^{19}F NMR (565 MHz, CDCl_3): δ -60.51 (s), -60.52 (s). HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{16}\text{F}_3\text{N}_3\text{O}_2\text{Na}$ 410.1087; Found 410.1074.

3-(1-(2-Aminophenyl)-5-methyl-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3h)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (44.0 mg, 66%, dr = 0.5:0.5), mp 91.2-93.0 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.38 (s, 1H), 7.28-7.23 (m, 1.5H), 7.00 (dd, $J_1 = 7.2$ Hz, $J_2 = 1.2$ Hz, 0.5H), 6.96 (d, $J = 8.4$ Hz, 1H), 6.85-6.78 (m, 3H), 6.47 (s, 0.5H), 6.46 (s, 0.5H), 4.08-4.04 (m, 1H), 3.69 (br s, 1H), 3.41 (br s, 1H), 2.93-2.81 (m, 5H), 2.42 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.8, 176.0, 175.8, 175.7, 144.9, 144.6, 136.4, 136.0, 135.9, 130.5, 130.4, 130.3, 130.2, 130.14, 130.11, 128.0, 127.9, 124.3, 122.0, 121.9, 120.4, 120.3, 118.9, 118.6, 116.6, 116.2, 110.14, 110.12, 101.9, 101.2, 39.2, 39.0, 36.4, 35.9, 25.1, 21.4. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_2\text{Na}$ 356.1369; Found 356.1363.

3-(1-(2-Aminophenyl)-5-methoxy-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3i)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (38.4 mg, 55%, dr = 0.5:0.5), mp 90.3-92.0 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.30-7.25 (m, 1.5H), 7.06 (d, $J = 1.8$ Hz, 1H), 7.01 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 0.5H), 6.87-6.79 (m, 4H), 6.49 (s, 0.5H), 6.48 (s, 0.5H), 4.10-4.05 (m, 1H), 3.84 (s, 3H), 3.70 (s, 1H), 3.40 (s, 1H), 2.96-2.83 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.8, 176.0, 175.8, 175.6, 155.0, 154.9, 144.9, 144.6, 136.4, 136.3, 133.2, 132.8, 130.5, 130.4, 130.4, 130.3, 128.1, 128.0, 122.0, 121.9, 118.9, 118.6, 116.7, 116.2, 112.8, 111.24, 111.21, 102.5, 102.4, 101.9, 101.4, 55.94, 55.93, 39.3, 39.0, 36.4, 35.9, 25.1. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_3\text{Na}$ 372.1319; Found 372.1306.

3-(1-(2-Aminophenyl)-5-fluoro-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3j)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (48.5 mg, 72%, dr = 0.5:0.5), mp 73.2-74.0 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.30-7.24 (m, 2.5H), 7.01 (dd, $J_1 = 7.2$ Hz, $J_2 = 1.2$ Hz, 0.5H), 6.91-6.81 (m, 4H), 6.531 (s, 0.5H), 6.526 (s, 0.5H), 4.11-4.07 (m, 1H), 3.70 (s, 1H), 3.39 (s, 1H), 2.98-2.83 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$

NMR (150 MHz, CDCl₃): δ 176.6, 175.8, 175.6, 175.5, 158.6 (d, $^1J_{C-F}$ = 234.3 Hz), 158.5 (d, $^1J_{C-F}$ = 234.3 Hz), 144.8, 144.5, 137.6, 137.5, 134.5, 134.1, 130.7, 130.6, 130.5, 130.2, 128.0 (d, $^3J_{C-F}$ = 7.2 Hz), 127.9 (d, $^3J_{C-F}$ = 7.5 Hz), 121.5, 119.1, 118.7, 116.8, 116.4, 111.2 (d, $^3J_{C-F}$ = 6.3 Hz), 111.18 (d, $^3J_{C-F}$ = 6.5 Hz), 111.16, 111.0, 105.6 (d, $^2J_{C-F}$ = 23.0 Hz), 105.5 (d, $^2J_{C-F}$ = 22.8 Hz), 102.2 (d, $^4J_{C-F}$ = 4.4 Hz), 101.7 (d, $^4J_{C-F}$ = 4.2 Hz), 39.2, 39.0, 36.3, 35.8, 25.2. ¹⁹F NMR (565 MHz, CDCl₃): δ -123.45 – -123.49 (m), -123.51 – -123.55 (m). HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆FN₃O₂Na 360.1119; Found 360.1106.

3-(1-(2-Aminophenyl)-5-chloro-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3k)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (47.3 mg, 67%, dr = 0.6:0.4), mp 83.9-85.6 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.57 (d, J = 1.8 Hz, 1H), 7.30-7.27 (m, 1.6H), 7.11-7.09 (m, 1H), 7.00 (dd, J_1 = 7.8 Hz, J_2 = 1.2 Hz, 0.4H), 6.88-6.81 (m, 3H), 6.52 (s, 0.4H), 6.51 (s, 0.6H), 4.11-4.07 (m, 1H), 3.69 (s, 0.8H), 3.39 (s, 1.2H), 2.98-2.82 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.5, 175.7, 175.5, 175.4, 144.7, 144.4, 137.4, 137.3, 136.3, 135.9, 130.8, 130.7, 130.4, 130.1, 128.7, 128.6, 126.53, 126.50, 123.0, 121.3, 120.1, 120.0, 119.1, 118.8, 116.8, 116.4, 111.6, 111.5, 101.9, 101.3, 39.2, 38.9, 36.2, 35.7, 25.2. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆ClN₃O₂Na 376.0823; Found 376.0820.

3-(1-(2-Aminophenyl)-5-bromo-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3l)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (51.6 mg, 65%, dr = 0.6:0.4), mp 80.0-81.5 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.73 (d, J = 0.6 Hz, 1H), 7.30-7.28 (m, 1.6H), 7.23 (d, J = 9.0 Hz, 1H), 7.00 (d, J = 7.2 Hz, 0.4H), 6.88-6.81 (m, 3H), 6.514 (s, 0.4H), 6.510 (s, 0.6H), 4.12-4.07 (m, 1H), 3.68 (s, 0.8H), 3.38 (s, 1.2H), 2.97-2.82 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.5, 175.7, 175.5, 175.4, 144.7, 144.4, 137.2, 137.1, 136.6, 136.2, 130.8, 130.7, 130.4, 130.1, 129.3, 129.2, 125.6, 123.2, 123.1, 121.3, 119.1, 118.8, 116.8, 116.4, 114.1, 114.0, 112.0, 111.9, 101.8, 101.2, 39.1, 38.9, 36.2, 35.7, 25.2. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₁₆BrN₃O₂Na 420.0318; Found 420.0303.

3-(1-(2-Aminophenyl)-4-methyl-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3m)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (37.3 mg, 56%, dr = 0.6:0.4), mp 209.0-209.5 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.30-7.26 (m, 1.4H), 7.07-7.01 (m, 1.6H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.87-6.77 (m, 3H), 6.59 (s, 0.6H), 6.58 (s, 0.4H), 4.14-4.10 (m, 1H), 3.68 (s, 1.2H), 3.40 (s, 0.8H), 2.93-2.87 (m, 5H), 2.55 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 176.1, 175.8, 175.7, 144.8, 144.5, 137.7, 137.3, 135.4, 135.3, 130.6, 130.5, 130.4, 130.3, 130.2, 127.6, 127.5, 122.9, 122.1, 122.0, 121.0, 120.9, 118.9, 118.6, 116.7, 116.3, 108.04, 108.01, 100.9, 100.2, 39.3, 39.0, 36.5, 36.0, 25.1, 18.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₉N₃O₂Na 356.1369; Found 356.1354.

3-(1-(2-Aminophenyl)-4-fluoro-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3n)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (41.8 mg, 62%, dr = 0.6:0.4), mp 155.0-156.2 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.30-7.26 (m, 1.6H), 7.07-7.03 (m, 1H), 7.01 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 0.4H), 6.88-6.79 (m, 3H), 6.74-6.71 (m, 1H), 6.66 (s, 0.4H), 6.65 (s, 0.6H), 4.12-4.06 (m, 1H), 3.71(br s, 0.8H), 3.42 (br s, 1.2H), 2.97-2.84 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.5, 175.7, 175.5, 175.4, 156.2 (d, ¹*J*_{C-F} = 247.7 Hz), 156.1 (d, ¹*J*_{C-F} = 248.1 Hz), 144.7, 144.4, 140.4 (d, ³*J*_{C-F} = 11.7 Hz), 140.0 (d, ³*J*_{C-F} = 10.4 Hz), 136.1, 136.0, 130.8, 130.7, 130.4, 130.1, 123.3, 123.2, 121.5, 121.4, 119.0, 118.7, 116.84 (d, ²*J*_{C-F} = 21.3 Hz), 116.83, 116.8 (d, ²*J*_{C-F} = 22.2 Hz), 116.4, 106.6 (d, ⁴*J*_{C-F} = 3.0 Hz), 106.5 (d, ⁴*J*_{C-F} = 3.3 Hz), 105.7 (d, ²*J*_{C-F} = 18.6 Hz), 105.6 (d, ²*J*_{C-F} = 18.9 Hz), 98.4, 97.7, 39.2, 38.9, 36.3, 35.7, 25.2. ¹⁹F NMR (565 MHz, CDCl₃): δ -122.12 (dd, *J*₁ = 10.2 Hz, *J*₂ = 5.7 Hz), -122.16 ((dd, *J*₁ = 9.6 Hz, *J*₂ = 5.1 Hz)). HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₆FN₃O₂Na 360.1119; Found 360.1100.

3-(1-(2-Aminophenyl)-7-fluoro-1*H*-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3o)

Eluent: petroleum ether/ethyl acetate (4:1). Yellow solid (39.8 mg, 59%, dr = 0.55:0.45), mp 137.8-138.7 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.35-7.30 (m, 1.45H), 7.24-7.21 (m, 1H), 7.06-6.99 (m, 1.55H), 6.83-6.75 (m, 3H), 6.57 (s, 1H), 4.07-4.01 (m, 1H), 3.57 (br s, 2H), 2.90-2.81 (m, 5H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 176.6, 175.8, 175.6, 175.4, 149.7 (d, ¹*J*_{C-F} = 246.2 Hz), 149.6 (d, ¹*J*_{C-F} = 246.3 Hz), 144.7, 144.6, 137.5, 137.4,

131.6 (d, $^3J_{\text{C-F}} = 8.7$ Hz), 131.5 (d, $^3J_{\text{C-F}} = 8.6$ Hz), 130.6, 130.5, 130.0, 129.9, 125.6 (d, $^2J_{\text{C-F}} = 35.7$ Hz), 125.5 (d, $^2J_{\text{C-F}} = 35.4$ Hz), 123.4, 123.3, 121.0 (d, $^4J_{\text{C-F}} = 2.4$ Hz), 120.9 (d, $^4J_{\text{C-F}} = 3.9$ Hz), 118.6, 118.3, 116.6 (d, $^3J_{\text{C-F}} = 6.4$ Hz), 116.5 (d, $^3J_{\text{C-F}} = 7.3$ Hz), 116.4, 116.0, 108.5 (d, $^2J_{\text{C-F}} = 16.9$ Hz), 108.4 (d, $^2J_{\text{C-F}} = 17.0$ Hz), 103.2, 102.5, 39.0, 38.7, 36.3, 35.9, 25.2, 25.1. ^{19}F NMR (376 MHz, CDCl_3): δ -135.64 (d, $J = 10.5$ Hz), -135.83 (d, $J = 11.3$ Hz). HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{16}\text{FN}_3\text{O}_2\text{Na}$ 360.1119; Found 360.1108.

3-(1-(2-Aminophenyl)-7-chloro-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3p)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (46.6 mg, 66%, dr = 0.5:0.5), mp 134.6-136.0 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.51-7.50 (m, 1H), 7.30 (td, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 0.5H), 7.27-7.25 (m, 1H), 7.13-7.12 (m, 1H), 7.06-7.02 (m, 1.5H), 6.85-6.76 (m, 2H), 6.59 (s, 0.5H), 6.58 (s, 0.5H), 4.05-4.01 (m, 1H), 3.47 (br s, 2H), 2.97-2.86 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 176.6, 175.8, 175.6, 175.5, 145.6, 145.5, 138.0, 137.9, 133.0, 132.6, 131.1, 131.0, 130.8, 130.7, 130.6, 130.4, 124.3, 124.2, 123.2, 122.9, 121.43, 121.40, 119.6, 119.5, 118.5, 118.1, 117.1, 117.0, 116.1, 115.7, 103.3, 102.5, 39.2, 38.9, 36.4, 35.9, 25.2, 25.1. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_3\text{O}_2\text{Na}$ 376.0823; Found 376.0813.

3-(1-(2-Amino-5-chlorophenyl)-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3q)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (40.9 mg, 58%, dr = 0.6:0.4), mp 82.1-83.6 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.62-7.61 (m, 1H), 7.36 (d, $J = 1.8$ Hz, 0.6H), 7.27 (d, $J = 2.4$ Hz, 0.6H), 7.25 (d, $J = 1.8$ Hz, 0.4H), 7.19-7.15 (m, 2H), 7.04 (d, $J = 2.4$ Hz, 0.4H), 6.97-6.94 (m, 1H), 6.83 (d, $J = 8.4$ Hz, 0.4H), 6.80 (d, $J = 9.0$ Hz, 0.6H), 6.59 (s, 0.4H), 6.57 (s, 0.6H), 4.11 (dd, $J_1 = 9.6$ Hz, $J_2 = 5.4$ Hz, 0.4H), 4.07 (dd, $J_1 = 9.6$ Hz, $J_2 = 4.8$ Hz, 0.6H), 3.76 (s, 0.8H), 3.43 (s, 1.2H), 3.05-2.83 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.6, 175.8, 175.5, 175.4, 143.7, 143.2, 137.8, 137.3, 135.9, 135.5, 130.6, 130.5, 130.4, 129.9, 127.8, 123.03, 123.01, 123.0, 122.7, 122.6, 121.14, 121.11, 120.9, 120.8, 117.6, 117.1, 110.4, 110.3, 102.9, 101.8, 39.1, 38.7, 36.3, 35.7, 25.23, 25.21. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_3\text{O}_2\text{Na}$ 376.0823; Found 376.0816.

3-(1-(2-Amino-5-bromophenyl)-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3r)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (47.7 mg, 60%, dr = 0.5:0.5), mp 102.3-103.5 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.62-7.59 (m, 1H), 7.49 (d, *J* = 2.0 Hz, 0.5H), 7.40-7.36 (m, 1H), 7.19-7.14 (m, 2.5H), 6.97-6.93 (m, 1H), 6.79-6.73 (m, 1H), 6.58 (s, 0.5H), 6.56 (s, 0.5H), 4.12-4.05 (m, 1H), 3.78 (br s, 1H), 3.46 (br s, 1H), 3.09-2.80 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.6, 175.8, 175.5, 175.4, 144.2, 143.7, 137.8, 137.3, 135.9, 135.5, 133.4, 133.3, 133.2, 132.8, 127.4, 123.0, 123.0, 122.9, 121.2, 121.1, 120.9, 120.8, 118.0, 117.5, 110.4, 110.3, 109.6, 109.2, 102.9, 101.8, 39.1, 38.7, 36.3, 35.7, 25.3, 25.2. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₇BrN₃O₂ 398.0499; Found 398.0491.

3-(1-(2-Amino-4-methoxyphenyl)-1H-indol-2-yl)-1-methylpyrrolidine-2,5-dione (3s)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (39.1 mg, 56%, dr = 0.55:0.45), mp 82.4-84.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.61-7.59 (m, 1H), 7.21 (d, *J* = 8.4 Hz, 0.45H), 7.16-7.12 (m, 2H), 6.98-6.95 (m, 1H), 6.93 (d, *J* = 8.4 Hz, 0.55H), 6.55 (s, 0.55H), 6.54 (s, 0.45H), 6.42 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 0.45H), 6.39-6.36 (m, 1.55H), 4.13-4.08 (m, 1H), 3.82 (s, 1.35H), 3.81 (s, 1.65H), 3.68 (s, 1.1H), 3.38 (s, 0.9H), 2.99-2.84 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.8, 176.0, 175.8, 175.6, 161.2, 145.9, 145.6, 138.3, 137.9, 136.3, 136.2, 131.4, 131.1, 127.7, 127.6, 122.6, 120.73, 120.70, 120.67, 120.6, 115.0, 114.9, 110.43, 110.40, 104.7, 104.5, 102.0, 101.4, 101.3, 101.2, 55.4, 39.2, 38.9, 36.4, 36.0, 25.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₉N₃O₃Na 372.1319; Found 372.1317.

3-(1-(2-Aminophenyl)-1H-indol-2-yl)-1-ethylpyrrolidine-2,5-dione (3t)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (40.0 mg, 60%, dr = 0.7:0.3), mp 201.0-202.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.63-7.60 (m, 1H), 7.33-7.26 (m, 1.3H), 7.17-7.13 (m, 2H), 7.04 (dd, *J*₁ = 7.6 Hz, *J*₂ = 1.2 Hz, 0.7H), 6.97-6.95 (m, 1H), 6.89-6.80 (m, 2H), 6.55 (s, 1H), 4.11-4.06 (m, 1H), 3.57-3.48 (m, 2H), 3.13 (br s, 2H), 2.98-2.81 (m, 2H), 1.17-1.12 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 176.5, 175.8, 175.5, 175.4, 144.9, 144.5, 137.9, 137.5, 136.3, 136.2, 130.6, 130.5, 130.4, 130.2, 127.8, 127.7, 122.7, 121.9, 120.8,

120.79, 120.7, 120.6, 119.0, 118.8, 116.7, 116.3, 110.5, 110.4, 101.8, 101.4, 39.0, 38.8, 36.4, 36.2, 34.14, 34.10, 13.00, 12.97. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{20}H_{19}N_3O_2Na$ 356.1369; Found 356.1352.

3-(1-(2-Aminophenyl)-1*H*-indol-2-yl)-1-benzylpyrrolidine-2,5-dione (3u)

Eluent: petroleum ether/ethyl acetate (4:1). White solid (41.1 mg, 52%, dr = 0.5:0.5), mp 94.0-95.0 °C. 1H NMR (600 MHz, $CDCl_3$): δ 7.58-7.57 (m, 1H), 7.35-7.34 (m, 2H), 7.29-7.23 (m, 4.5H), 7.14-7.11 (m, 2H), 7.00 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 0.5H), 6.95-6.93 (m, 1H), 6.86-6.83 (m, 1H), 6.79-6.73 (m, 1H), 6.47 (s, 0.5H), 6.46 (s, 0.5H), 4.62-4.56 (m, 2H), 4.06-4.03 (m, 1H), 3.67 (s, 1H), 3.36 (s, 1H), 2.92-2.79 (m, 2H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 176.3, 175.7, 175.4, 175.2, 144.9, 144.5, 137.9, 137.5, 136.3, 136.2, 135.7, 135.6, 130.6, 130.5, 130.4, 130.2, 128.9, 128.8, 128.7, 128.1, 128.0, 127.8, 127.7, 122.7, 121.8, 121.7, 120.83, 120.81, 120.8, 120.7, 119.0, 118.7, 116.7, 116.3, 110.6, 110.4, 101.8, 101.3, 42.8, 42.7, 39.0, 38.8, 36.4, 36.3. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{25}H_{21}N_3O_2Na$ 418.1526; Found 418.1503.

3-(1-(2-Aminophenyl)-1*H*-pyrrol-2-yl)-1-methylpyrrolidine-2,5-dione (3v)

Eluent: petroleum ether/ethyl acetate (4:1). Yellow syrup (33.9 mg, 63%, dr = 0.45:0.55). 1H NMR (600 MHz, $CDCl_3$): δ 7.20 (d, $J = 7.8$ Hz, 0.45H), 7.11 (t, $J = 7.8$ Hz, 1H), 6.92 (d, $J = 7.2$ Hz, 0.55H), 6.71-6.59 (m, 3H), 6.20-6.19 (m, 1H), 6.08-6.07 (m, 1H), 3.85-3.80 (m, 1H), 3.76 (br s, 1.1H), 3.44 (br s, 0.9H), 2.85-2.66 (m, 5H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 176.5, 175.6, 175.0, 174.9, 143.2, 143.0, 129.0, 128.9, 128.4, 128.1, 127.8, 127.7, 123.6, 123.5, 122.2, 121.9, 117.3, 117.0, 115.3, 114.8, 108.2, 106.8, 106.6, 37.5, 37.3, 35.5, 35.3, 24.0, 23.9. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{15}H_{16}N_3O_2$ 270.1237; Found 270.1238.

2. Typical procedure for the synthesis of 4a and spectroscopic data of 4a-4y

To a reaction tube equipped with a stir bar were added 2-(1*H*-indol-1-yl)aniline (**1a**, 41.6 mg, 0.2 mmol), EA (2 mL), *N*-methylmaleimide (**2a**, 33.3 mg, 0.3 mmol), [Ru(*p*-cymene)Cl₂]₂ (6.12 mg, 0.01 mmol), AgSbF₆ (13.7 mg, 0.04 mmol) and AcOH (57 μL, 1.0 mmol) with stirring. The mixture was stirred at 80 °C under air for 12 h. After being cooled to room temperature, it was added with BF₃·Et₂O (49 μL, 0.4 mmol). The resulting mixture was stirred at 100 °C under air for 10 h. Upon completion, it was cooled to ambient temperature, quenched with saturated aqueous solution of NaHCO₃ (1 mL), filtered through a pad of celite, and extracted with CH₂Cl₂ (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (6:1) as eluent to afford **4a**. **4b-4y** were obtained in a similar manner except for that the reaction for the synthesis of **4y** was carried out at 60 °C and 80 °C for the two steps, respectively.

11-Methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (**4a**)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (33.1 mg, 55%), mp 178.1-178.9 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 1H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.42 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 7.38-7.34 (m, 1H), 7.29-7.25 (m, 1H), 7.23-7.15 (m, 2H), 6.37 (s, 1H), 4.02-4.00 (m, 1H), 3.21-3.04 (m, 5H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.2, 161.6, 140.2, 139.9, 136.6, 129.9, 128.9, 127.7, 126.8, 125.0, 124.8, 122.7, 121.2, 120.9, 111.1, 98.0, 34.8, 31.9, 26.3. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₆N₃O 302.1288; Found 302.1278.

3,11-Dimethyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (**4b**)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (32.1 mg, 51%), mp 172.0-173.5 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.77 (d, *J* = 7.8 Hz, 1H), 7.50 (d, *J* = 7.8 Hz, 1H), 7.43-7.40 (m, 2H), 7.35 (t, *J* = 7.8 Hz, 1H), 7.28 (t, *J* = 7.8 Hz, 1H), 7.01 (d, *J* = 7.8 Hz, 1H), 6.31 (s, 1H), 3.99 (d, *J* = 8.4 Hz, 1H), 3.18-3.04 (m, 5H), 2.45 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.3, 161.7, 140.2, 139.4, 137.0, 132.6, 130.0, 127.7, 126.7,

125.1, 124.7, 122.9, 120.5, 111.0, 97.8, 34.8, 31.9, 26.3, 22.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₀H₁₈N₃O 316.1444; Found 316.1438.

3-Methoxy-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one (4c)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (28.5 mg, 43%), mp 185.4-186.6 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.76 (d, *J* = 7.8 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 1H), 7.41 (d, *J* = 7.8 Hz, 1H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.27 (t, *J* = 7.8 Hz, 1H), 7.12 (s, 1H), 6.84 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 6.29 (s, 1H), 3.99 (d, *J* = 8.4 Hz, 1H), 3.81 (s, 3H), 3.16-3.04 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.3, 161.9, 156.8, 140.3, 139.1, 137.4, 129.9, 127.7, 126.8, 124.8, 124.7, 123.0, 121.4, 110.8, 97.8, 95.1, 55.8, 34.7, 31.9, 26.3. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₀H₁₈N₃O₂ 332.1394; Found 332.1382.

3-Fluoro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one (4d)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (35.1 mg, 55%), mp 188.5-189.8 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.71 (d, *J* = 7.8 Hz, 1H), 7.53 (dd, *J*₁ = 8.4 Hz, *J*₂ = 5.4 Hz, 1H), 7.42 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 1H), 7.37 (t, *J* = 7.8 Hz, 1H), 7.32-7.27 (m, 2H), 6.94 (td, *J*₁ = 9.0 Hz, *J*₂ = 1.8 Hz, 1H), 6.35 (s, 1H), 4.02 (d, *J* = 8.4 Hz, 1H), 3.18-3.06 (m, 5H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.1, 161.7, 160.1 (d, ¹*J*_{C-F} = 237.5 Hz), 140.4 (d, ⁴*J*_{C-F} = 4.2 Hz), 140.2, 136.6 (d, ³*J*_{C-F} = 12.0 Hz), 129.6, 127.8, 127.1, 125.3, 125.0, 124.5, 121.6 (d, ³*J*_{C-F} = 9.8 Hz), 109.8 (d, ²*J*_{C-F} = 24.9 Hz), 97.9, 97.8 (d, ²*J*_{C-F} = 27.2 Hz), 34.8, 31.8, 26.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -119.18 (td, *J*₁ = 9.8 Hz, *J*₂ = 6.0 Hz). HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₁₅FN₃O 320.1194; Found 320.1187.

3-Chloro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one (4e)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (37.5 mg, 56%), mp 236.1-236.6 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, *J* = 7.6 Hz, 1H), 7.60 (s, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.43-7.35 (m, 2H), 7.31-7.27 (m, 1H), 7.12 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 6.34 (s, 1H), 3.98 (d, *J* = 7.2 Hz, 1H), 3.17-3.03 (m, 5H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.0, 161.6, 140.7, 140.2, 136.9, 129.4, 128.6, 127.8, 127.4, 127.2, 125.0, 124.8, 121.8, 121.7, 111.1, 98.0, 34.8, 31.8, 26.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅ClN₃O 336.0898; Found 336.0879.

3-Bromo-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4f)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (37.1 mg, 49%), mp 232.8-233.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.76 (s, 1H), 7.72 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.42 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 1H), 7.40-7.37 (m, 1H), 7.32-7.29 (m, 1H), 7.27 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 6.35 (s, 1H), 4.00-3.98 (m, 1H), 3.16 (dd, *J*₁ = 18.0 Hz, *J*₂ = 2.4 Hz, 1H), 3.12 (s, 3H), 3.08 (dd, *J*₁ = 18.6 Hz, *J*₂ = 9.0 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.5, 140.5, 140.2, 137.3, 129.3, 127.8, 127.7, 127.3, 125.0, 124.8, 124.4, 122.1, 116.2, 114.0, 98.0, 34.7, 31.8, 26.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅BrN₃O 380.0393; Found 380.0373.

11-Methyl-3-(trifluoromethyl)-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4g)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (45.0 mg, 61%), mp 211.0-213.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.89 (s, 1H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.45-7.41 (m, 3H), 7.35-7.33 (m, 1H), 6.45 (s, 1H), 4.05 (d, *J* = 7.8 Hz, 1H), 3.22-3.10 (m, 5H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ. 174.9, 161.4, 142.4, 140.3, 135.6, 131.3, 129.2, 127.9, 127.5, 125.2, 125.0 (q, ¹*J*_{C-F} = 269.8 Hz), 124.79, 124.77 (q, ²*J*_{C-F} = 31.8 Hz), 121.3, 117.8 (q, ³*J*_{C-F} = 3.9 Hz), 108.6 (q, ³*J*_{C-F} = 3.9 Hz), 98.1, 34.9, 31.8, 26.4. ¹⁹F NMR (565 MHz, CDCl₃): δ -60.60 (s). HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₅F₃N₃O 370.1162; Found 370.1151.

2,11-Dimethyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one (4h)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (33.4 mg, 53%), mp 239.4-240.5 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, *J* = 8.0 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 1H), 7.41-7.39 (m, 2H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.25 (t, *J* = 7.2 Hz, 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 6.27 (s, 1H), 3.95 (d, *J* = 8.0 Hz, 1H), 3.15 (dd, *J*₁ = 18.4 Hz, *J*₂ = 2.4 Hz, 1H), 3.10 (s, 3H), 3.03 (dd, *J*₁ = 18.0 Hz, *J*₂ = 8.8 Hz, 1H), 2.43 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.3, 161.6, 140.1, 139.9, 134.9, 130.6, 130.0, 129.2, 127.7, 126.6, 124.9, 124.8, 124.2, 120.6, 110.8, 97.6, 34.8, 31.9, 26.3, 21.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₈N₃O 316.1444; Found 316.1434.

2-Methoxy-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one

(4i)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (27.8 mg, 42%), mp 229.7-230.8 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, *J* = 7.6 Hz, 1H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.40 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 1H), 7.35-7.31 (m, 1H), 7.27-7.23 (m, 1H), 7.06 (d, *J* = 2.0 Hz, 1H), 6.85 (dd, *J*₁ = 8.8 Hz, *J*₂ = 2.0 Hz, 1H), 6.27 (s, 1H), 3.93 (d, *J* = 7.6 Hz, 1H), 3.83 (s, 3H), 3.14 (dd, *J*₁ = 18.4 Hz, *J*₂ = 2.8 Hz, 1H), 3.10 (s, 3H), 3.04 (dd, *J*₁ = 18.4 Hz, *J*₂ = 9.2 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.2, 161.5, 155.0, 140.2, 140.0, 131.7, 130.0, 129.6, 127.7, 126.6, 124.81, 124.77, 112.5, 112.0, 102.6, 97.7, 55.9, 34.8, 31.9, 26.3. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₈N₃O₂ 332.1394; Found 332.1391.

2-Fluoro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one

(4j)

Eluent: petroleum ether/ethyl acetate 6:1). White solid (38.3 mg, 60%), mp 214.8-215.8 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.72-7.71 (m, 1H), 7.53 (dd, *J*₁ = 9.0 Hz, *J*₂ = 4.2 Hz, 1H), 7.42 (dd, *J*₁ = 7.8 Hz, *J*₂ = 0.6 Hz, 1H), 7.38-7.35 (m, 1H), 7.29-7.24 (m, 2H), 6.94 (td, *J*₁ = 9.0 Hz, *J*₂ = 2.4 Hz, 1H), 6.33 (s, 1H), 3.98 (d, *J* = 7.8 Hz, 1H), 3.16 (dd, *J*₁ = 18.0 Hz, *J*₂ = 2.4 Hz, 1H), 3.12 (s, 3H), 3.07 (dd, *J*₁ = 18.6 Hz, *J*₂ = 9.0 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.1, 161.5, 158.4 (d, ¹*J*_{C-F} = 235.8 Hz), 141.3, 140.1, 133.1, 129.7, 129.4 (d, ³*J*_{C-F}

= 9.0 Hz), 127.8, 127.0, 124.9, 124.7, 112.0 (d, $^3J_{C-F}$ = 9.0 Hz), 110.8 (d, $^2J_{C-F}$ = 25.2 Hz), 105.8 (d, $^2J_{C-F}$ = 23.1 Hz), 97.9 (d, $^4J_{C-F}$ = 4.1 Hz), 34.8, 31.8, 26.4. ^{19}F NMR (376 MHz, CDCl_3): δ -122.65 (td, J_1 = 9.0 Hz, J_2 = 4.1 Hz). HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{FN}_3\text{O}$ 320.1194; Found 320.1178.

2-Chloro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4k)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (34.2 mg, 51%), mp 209.2-210.4 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.69 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.51 (d, J = 9.0 Hz, 1H), 7.42 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 1H), 7.38-7.36 (m, 1H), 7.29-7.26 (m, 1H), 7.14 (dd, J_1 = 9.0 Hz, J_2 = 1.8 Hz, 1H), 6.30 (s, 1H), 3.98 (d, J = 7.8 Hz, 1H), 3.15 (dd, J_1 = 18.0 Hz, J_2 = 2.4 Hz, 1H), 3.11 (s, 3H), 3.07 (dd, J_1 = 18.0 Hz, J_2 = 9.0 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 175.0, 161.5, 141.1, 140.2, 134.9, 130.0, 129.5, 127.8, 127.1, 126.7, 124.9, 124.8, 122.9, 120.3, 112.2, 97.5, 34.8, 31.8, 26.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{ClN}_3\text{O}$ 336.0898; Found 336.0883.

2-Bromo-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4l)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (41.7 mg, 55%), mp 203.7-204.7 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.73 (d, J = 1.8 Hz, 1H), 7.69 (dd, J_1 = 7.8 Hz, J_2 = 0.6 Hz, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.42 (dd, J_1 = 7.8 Hz, J_2 = 1.8 Hz, 1H), 7.39-7.36 (m, 1H), 7.29-7.26 (m, 2H), 6.31 (s, 1H), 3.99 (d, J = 7.8 Hz, 1H), 3.16 (dd, J_1 = 18.6 Hz, J_2 = 3.0 Hz, 1H), 3.12 (s, 3H), 3.08 (dd, J_1 = 18.0 Hz, J_2 = 9.0 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 175.0, 161.5, 141.0, 140.2, 135.2, 130.6, 129.5, 127.8, 127.2, 125.5, 124.9, 124.8, 123.4, 114.2, 112.6, 97.4, 34.8, 31.8, 26.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{BrN}_3\text{O}$ 380.0393; Found 380.0381.

1,11-Dimethyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4m)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (25.8 mg, 41%), mp 218.5-218.9 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 8.0 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.2 Hz, 1H), 7.29-7.25 (m, 1H), 7.13 (t, *J* = 7.6 Hz, 1H), 6.98 (d, *J* = 6.8 Hz, 1H), 6.39 (s, 1H), 4.03 (d, *J* = 8.8 Hz, 1H) 3.25-3.06 (m, 5H), 2.55 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.3, 161.7, 140.2, 139.3, 136.4, 130.4, 130.0, 128.7, 127.6, 126.8, 125.1, 124.8, 122.8, 121.4, 108.7, 96.4, 34.8, 31.9, 26.3, 18.7. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₈N₃O 316.1444; Found 316.1444.

1-Fluoro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one
(4n)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (32.5 mg, 51%), mp 182.7-183.7 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.74 (d, *J* = 7.8 Hz, 1H), 7.43-7.37 (m, 3H), 7.28 (t, *J* = 7.8 Hz, 1H), 7.14-7.11 (m, 1H), 6.86-6.83 (m, 1H), 6.48 (s, 1H), 4.01 (d, *J* = 8.4 Hz, 1H), 3.20 (dd, *J*₁ = 18.6 Hz, *J*₂ = 2.4 Hz, 1H), 3.13-3.08 (m, 4H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.7, 156.1 (d, ¹*J*_{C-F} = 246.0 Hz), 140.2, 139.9, 138.9 (d, ³*J*_{C-F} = 10.5 Hz), 129.6, 127.8, 127.2, 125.0, 124.9, 123.2 (d, ³*J*_{C-F} = 7.5 Hz), 118.0 (d, ²*J*_{C-F} = 21.9 Hz), 107.2 (d, ⁴*J*_{C-F} = 3.9 Hz), 106.0 (d, ²*J*_{C-F} = 17.4 Hz), 93.9, 34.7, 31.8, 26.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -121.94 – -121.98 (m). HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅FN₃O 320.1194; Found 320.1194.

1-Chloro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one
(4o)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (34.8 mg, 52%), mp 191.1-191.8 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.72 (d, *J* = 7.2 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.38 (t, *J* = 7.2 Hz, 1H), 7.28 (t, *J* = 7.2 Hz, 1H), 7.18 (d, *J* = 7.2 Hz, 1H), 7.13 (t, *J* = 7.2 Hz, 1H), 6.51 (s, 1H), 4.03 (d, *J* = 8.4 Hz, 1H) 3.23 (d, *J* = 18.0 Hz, 1H), 3.13-3.09 (m, 4H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.6, 140.5, 140.3, 137.2, 129.5, 127.8, 127.7, 127.3, 126.1, 125.0, 124.9, 123.2, 120.9, 109.8, 96.6, 34.8, 31.8, 26.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅ClN₃O 336.0898; Found 336.0890.

4-Fluoro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one

(4p)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (33.8 mg, 53%), mp 172.6-173.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.47 (t, *J* = 7.8 Hz, 1H), 7.39 (d, *J* = 7.8 Hz, 1H), 7.35-7.33 (m, 2H), 7.24-7.21 (m, 1H), 7.11-7.08 (m, 1H), 6.95-6.92 (m, 1H), 6.45 (s, 1H), 3.95 (d, *J* = 7.8 Hz, 1H), 3.17-3.14 (m, 4H), 3.08 (dd, *J*₁ = 18.0 Hz, *J*₂ = 9.0 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.9, 149.3 (d, ¹*J*_{C-F} = 247.3 Hz), 142.4, 140.2, 132.7 (d, ³*J*_{C-F} = 3.8 Hz), 130.1 (d, ⁴*J*_{C-F} = 2.1 Hz), 127.0, 126.8 (d, ⁵*J*_{C-F} = 7.1 Hz), 126.2, 124.3 (d, ²*J*_{C-F} = 8.4 Hz), 124.2, 121.5 (d, ³*J*_{C-F} = 7.2 Hz), 116.6 (d, ⁴*J*_{C-F} = 3.3 Hz), 109.1 (d, ²*J*_{C-F} = 19.2 Hz), 99.5 (d, ⁴*J*_{C-F} = 2.1 Hz), 34.6, 32.0, 26.4. ¹⁹F NMR (565 MHz, CDCl₃): δ -121.97 – -122.01 (m). HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅FN₃O 320.1194; Found 320.1189.

4-Chloro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one

(4q)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (33.5 mg, 50%), mp 173.0-174.0 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.54 (dd, *J*₁ = 8.0 Hz, *J*₂ = 0.8 Hz, 1H), 7.36-7.33 (m, 2H), 7.30-7.16 (m, 3H), 7.11 (t, *J* = 8.0 Hz, 1H), 6.48 (d, *J* = 1.2 Hz, 1H), 3.96-3.93 (m, 1H), 3.18-3.12 (m, 4H), 3.07 (dd, *J*₁ = 18.4 Hz, *J*₂ = 8.8 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 162.5, 144.1, 141.0, 132.8, 131.9, 129.5, 129.0, 127.1, 125.6, 125.0, 123.3, 121.9, 119.4, 117.7, 99.9, 34.7, 32.0, 26.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅ClN₃O 336.0898; Found 336.0890.

8-Methoxy-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-a]indol-12(11H)-one

(4r)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (27.2 mg, 41%), mp 201.0-202.8 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, *J* = 9.2 Hz, 1H), 7.61 (d, *J* = 7.6 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.22-7.13 (m, 2H), 6.93 (d, *J* = 2.8 Hz, 1H), 6.84 (dd, *J*₁ = 8.8 Hz, *J*₂ = 2.8 Hz, 1H), 6.35 (s, 1H), 4.00 (d, *J* = 8.4 Hz, 1H), 3.88 (s,

3H), 3.18 (dd, $J_1 = 18.4$ Hz, $J_2 = 2.4$ Hz, 1H), 3.10-3.03 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 175.6, 162.3, 158.5, 141.7, 139.9, 137.0, 129.1, 126.2, 123.5, 122.9, 121.32, 121.26, 112.2, 111.5, 111.3, 97.8, 56.1, 35.3, 32.2, 26.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{18}\text{N}_3\text{O}_2$ 332.1394; Found 332.1385.

7-Fluoro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one
(4s)

Eluent: petroleum ether/ethyl acetate (6:1). Red solid (30.6 mg, 48%), mp 117.0-118.0 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.64-7.62 (m, 2H), 7.51 (dd, $J_1 = 9.0$ Hz, $J_2 = 1.8$ Hz, 1H), 7.38 (dd, $J_1 = 8.4$ Hz, $J_2 = 6.0$ Hz, 1H), 7.24 (d, $J = 8.4$ Hz, 1H), 7.19 (t, $J = 7.2$ Hz, 1H), 7.10-7.07 (m, 1H), 6.38 (s, 1H), 4.01 (d, $J = 8.4$ Hz, 1H), 3.18 (d, $J = 18.6$ Hz, 1H), 3.10-3.07 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 175.0, 161.5, 159.1 (d, $^1J_{\text{C-F}} = 243.0$ Hz), 139.6, 136.6 (d, $^4J_{\text{C-F}} = 2.7$ Hz), 136.4, 130.5 (d, $^3J_{\text{C-F}} = 10.5$ Hz), 129.1 (d, $^3J_{\text{C-F}} = 8.1$ Hz), 129.0, 123.0, 121.6, 121.1, 114.0 (d, $^2J_{\text{C-F}} = 21.6$ Hz), 111.6 (d, $^2J_{\text{C-F}} = 24.9$ Hz), 110.9, 98.6, 34.7, 31.9, 26.3. ^{19}F NMR (565 MHz, CDCl_3): δ -116.62 – -116.66 (m). HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{FN}_3\text{O}$ 320.1194; Found 320.1186.

7-Chloro-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one
(4t)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (30.1 mg, 45%), mp 234.9-235.3 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.78 (d, $J = 2.0$ Hz, 1H), 7.63 (d, $J = 8.4$ Hz, 2H), 7.36-7.30 (m, 2H), 7.28-7.24 (m, 1H), 7.20 (t, $J = 7.6$ Hz, 1H), 6.39 (s, 1H), 4.01 (dd, $J_1 = 8.8$ Hz, $J_2 = 1.6$ Hz, 1H), 3.19 (dd, $J_1 = 18.4$ Hz, $J_2 = 2.8$ Hz, 1H), 3.13-3.06 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 175.0, 161.9, 139.6, 138.8, 136.4, 130.7, 129.7, 129.0, 128.9, 126.9, 124.7, 123.1, 121.6, 121.1, 110.9, 98.7, 34.8, 31.9, 26.4. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{ClN}_3\text{O}$ 336.0898; Found 336.0891.

7-Bromo-11-methyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one
(4u)

Eluent: petroleum ether/ethyl acetate (6:1). Red solid (34.9 mg, 46%), mp 243.8-244.7 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.91 (s, 1H), 7.61 (d, *J* = 7.8 Hz, 2H), 7.45 (d, *J* = 7.2 Hz, 1H), 7.28-7.24 (m, 2H), 7.19 (t, *J* = 7.2 Hz, 1H), 6.38 (s, 1H), 3.98 (d, *J* = 8.4 Hz, 1H), 3.17 (d, *J* = 18.0 Hz, 1H), 3.10-3.06 (m, 4H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.9, 139.6, 139.3, 136.4, 131.0, 129.8, 129.2, 129.0, 127.6, 123.1, 121.6, 121.1, 117.1, 110.8, 98.7, 34.8, 31.9, 26.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅BrN₃O 380.0393; Found 380.0390.

11-Ethyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4v)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (31.5 mg, 50%), mp 179.5-180.5 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.78 (d, *J* = 7.8 Hz, 1H), 7.65-7.63 (m, 2H), 7.41 (d, *J* = 7.2 Hz, 1H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.27 (t, *J* = 7.8 Hz, 1H), 7.22 (t, *J* = 7.8 Hz, 1H), 7.18 (t, *J* = 7.2 Hz, 1H), 6.38 (s, 1H), 4.00 (d, *J* = 8.4 Hz, 1H), 3.78-3.73 (m, 1H), 3.69-3.64 (m, 1H), 3.17 (dd, *J*₁ = 18.0 Hz, *J*₂ = 2.4 Hz, 1H), 3.07 (dd, *J*₁ = 18.6 Hz, *J*₂ = 8.4 Hz, 1H), 1.19 (t, *J* = 7.2 Hz, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 161.0, 140.2, 140.0, 136.6, 129.9, 129.0, 127.7, 126.7, 124.9, 124.7, 122.6, 121.1, 120.9, 111.1, 97.9, 35.0, 34.7, 31.9, 12.6. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₈N₃O 316.1444; Found 316.1433.

11-Benzyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4w)

Eluent: petroleum ether/ethyl acetate (6:1). Gray solid (31.7 mg, 42%), mp 249.5-250.1 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.77 (d, *J* = 7.8 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 2H), 7.42-7.39 (m, 3H), 7.35-7.33 (m, 1H), 7.27-7.20 (m, 5H), 7.17 (t, *J* = 7.8 Hz, 1H), 6.38 (s, 1H), 4.86 (d, *J* = 13.8 Hz, 1H), 4.74 (d, *J* = 14.4 Hz, 1H), 4.01 (d, *J* = 8.4 Hz, 1H), 3.19 (dd, *J*₁ = 18.6 Hz, *J*₂ = 2.4 Hz, 1H), 3.08 (dd, *J*₁ = 18.0 Hz, *J*₂ = 9.0 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.0, 160.8, 140.1, 139.9, 136.6, 136.0, 129.9, 129.0, 128.8, 128.5, 127.8, 127.7, 126.7, 124.9, 124.8, 122.6, 121.1, 120.9, 111.1, 98.1, 43.5, 34.8, 31.9. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₀N₃O 378.1601; Found 378.1599.

11-Isobutyl-13,13a-dihydrobenzo[2,3]pyrrolo[2',3':5,6][1,4]diazepino[1,7-*a*]indol-12(11*H*)-one (4x)

Eluent: petroleum ether/ethyl acetate (6:1). White solid (30.8 mg, 45%), mp 240.4-241.5 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.78 (d, *J* = 7.6 Hz, 1H), 7.65-7.62 (m, 2H), 7.39 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 7.37-7.33 (m, 1H), 7.29-7.27 (m, 1H), 7.22-7.16 (m, 2H), 6.38 (s, 1H), 4.00 (d, *J* = 7.6 Hz, 1H), 3.53 (dd, *J*₁ = 13.2 Hz, *J*₂ = 7.6 Hz, 1H), 3.44 (dd, *J*₁ = 13.2 Hz, *J*₂ = 7.6 Hz, 1H), 3.19 (dd, *J*₁ = 18.4 Hz, *J*₂ = 2.4 Hz, 1H), 3.08 (dd, *J*₁ = 18.4 Hz, *J*₂ = 9.2 Hz, 1H), 2.19-2.09 (m, 1H), 0.84-0.80 (m, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.5, 161.6, 140.3, 140.1, 136.5, 129.8, 129.0, 127.7, 126.7, 124.9, 124.6, 122.5, 121.1, 120.9, 111.1, 97.7, 47.1, 34.6, 31.7, 26.5, 20.1, 20.0. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₂H₂₂N₃O 344.1757; Found 344.1757.

10-Methyl-12,12a-dihydrobenzo[*b*]dipyrrolo[1,2-*d*:3',2'-*f*][1,4]diazepin-11(10*H*)-one (4y)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (26.1 mg, 52%), mp 127.2-128.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.46 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 7.36-7.34 (m, 1H), 7.30 (td, *J*₁ = 7.2 Hz, *J*₂ = 1.2 Hz, 1H), 7.23-7.20 (m, 1H), 7.08-7.07 (m, 1H), 6.36-6.35 (m, 1H), 6.02-6.01 (m, 1H), 3.83 (dd, *J*₁ = 8.4 Hz, *J*₂ = 3.0 Hz, 1H), 3.14 (s, 3H), 3.11-3.02 (m, 2H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 175.5, 161.6, 138.6, 131.9, 131.6, 128.0, 126.6, 125.3, 123.8, 121.5, 110.4, 104.2, 34.3, 32.2, 26.3. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₄N₃O 252.1131; Found 252.1134.

3. Typical procedure for the synthesis of 5a and spectroscopic data of 5a-5f²

To a reaction tube equipped with a stir bar were added **3a** (63.8 mg, 0.2 mmol), DMF (2 mL), DEAD (31.5 μ L, 0.2 mmol) and K_2CO_3 (138.2 mg, 1 mmol) with stirring. The mixture was stirred at room temperature for 2 h. Afterwards, it was quenched with water, filtered through a pad of celite, and extracted with CH_2Cl_2 (10 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (6:1) as eluent to afford **5a**. **5b-5f** were obtained in a similar manner.

3-(1-(2-Aminophenyl)-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (**5a**)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (39.9 mg, 63%), mp 197.5-198.4 $^{\circ}C$. 1H NMR (400 MHz, $CDCl_3$): δ 7.93 (s, 1H), 7.74 (d, $J = 7.6$ Hz, 1H), 7.34 (t, $J = 7.2$ Hz, 1H), 7.26-7.25 (m, 1H), 7.18 (t, $J = 7.6$ Hz, 1H), 7.08 (d, $J = 7.2$ Hz, 1H), 6.99 (d, $J = 8.0$ Hz, 1H), 6.90-6.85 (m, 2H), 5.54 (s, 1H), 3.50 (br s, 2H), 2.98 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 171.3, 170.5, 144.2, 140.5, 134.4, 131.0, 129.7, 128.2, 127.9, 126.0, 122.7, 122.5, 121.6, 119.3, 118.7, 116.6, 112.7, 110.7, 23.8. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{19}H_{16}N_3O_2$ 318.1237; Found 318.1228.

3-(1-(2-Aminophenyl)-6-methyl-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (**5b**)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (46.5 mg, 70%), mp 195.4-195.8 $^{\circ}C$. 1H NMR (600 MHz, $CDCl_3$): δ 7.89 (s, 1H), 7.61 (d, $J = 8.4$ Hz, 1H), 7.35-7.32 (m, 1H), 7.07 (dd, $J_1 = 7.2$ Hz, $J_2 = 1.2$ Hz, 1H), 7.01 (d, $J = 7.8$ Hz, 1H), 6.90-6.86 (m, 2H), 6.76 (s, 1H), 5.47 (s, 1H), 3.52 (s, 2H), 2.96 (s, 3H), 2.39 (s, 3H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 171.4, 170.6, 144.3, 141.0, 136.7, 134.5, 130.9, 129.7, 127.8, 125.9, 123.7, 122.7, 122.3, 119.3, 117.7, 116.6, 112.8, 110.4, 23.8, 22.1. HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{20}H_{18}N_3O_2$ 332.1394; Found 332.1381.

3-(1-(2-Aminophenyl)-5-methyl-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (**5c**)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (40.5 mg, 61%), mp 198.7-199.7 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.85 (s, 1H), 7.51 (s, 1H), 7.34-7.31 (m, 1H), 7.09 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 7.06 (dd, *J*₁ = 7.2 Hz, *J*₂ = 1.2 Hz, 1H), 6.89-6.85 (m, 3H), 5.51 (s, 1H), 3.50 (s, 2H), 2.98 (s, 3H), 2.44 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 171.4, 170.5, 144.2, 139.1, 134.5, 131.0, 130.9, 129.6, 128.2, 128.1, 127.9, 122.7, 122.0, 119.3, 118.3, 116.6, 112.2, 110.4, 23.8, 21.4. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₁₈N₃O₂ 332.1394; Found 332.1385.

3-(1-(2-Aminophenyl)-4-fluoro-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (5d)

Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (38.2 mg, 57%), mp 218.3-220.5 °C. ¹H NMR (600 MHz, CDCl₃): δ 8.00 (s, 1H), 7.37-7.34 (m, 1H), 7.20-7.17 (m, 1H), 7.09 (dd, *J*₁ = 7.2 Hz, *J*₂ = 1.2 Hz, 1H), 6.92-6.88 (m, 2H), 6.86-6.83 (m, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 5.57 (s, 1H), 3.51 (s, 2H), 3.01 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 171.1, 170.2, 157.2 (d, ¹*J*_{C-F} = 250.8 Hz), 144.0, 142.5 (d, ³*J*_{C-F} = 10.4 Hz), 134.0, 131.2, 129.5, 128.1, 126.5 (d, ³*J*_{C-F} = 7.7 Hz), 122.2, 119.6, 119.4, 117.6 (d, ²*J*_{C-F} = 23.0 Hz), 116.7, 108.3, 106.8 (d, ⁴*J*_{C-F} = 2.6 Hz), 106.1 (d, ²*J*_{C-F} = 18.5 Hz), 23.9. ¹⁹F NMR (565 MHz, CDCl₃): δ -119.46 – -119.48 (m). HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₄FN₃O₂Na 358.0962; Found 358.0954.

3-(1-(2-Aminophenyl)-7-chloro-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (5e)


Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (46.6 mg, 66%), mp 191.1-193.0 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.97 (s, 1H), 7.67 (d, *J* = 8.4 Hz, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.25 (d, *J* = 7.2 Hz, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 7.07 (d, *J* = 7.8 Hz, 1H), 6.85-6.82 (m, 2H), 5.48 (s, 1H), 3.56 (s, 2H), 3.02 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 171.1, 170.4, 145.2, 135.2, 133.8, 131.3, 130.6, 130.4, 129.8, 127.3, 123.9, 122.0, 121.5, 120.3, 118.8, 117.5, 116.0, 113.0, 23.9. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅ClN₃O₂ 352.0847; Found 352.0844.

3-(1-(2-Amino-5-chlorophenyl)-1*H*-indol-2-yl)-1-methyl-1*H*-pyrrole-2,5-dione (5f)


Eluent: petroleum ether/ethyl acetate (6:1). Yellow solid (41.8 mg, 60%), mp 191.3-191.6 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.93 (s, 1H), 7.74 (d, *J* = 8.4 Hz, 1H), 7.33-7.28 (m, 2H), 7.20 (t, *J* = 1.2 Hz, 1H), 7.10 (d, *J* = 2.4 Hz, 1H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.85 (d, *J* = 9.0 Hz, 1H), 5.63 (s, 1H), 3.57 (s, 2H), 3.00 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 171.1, 170.3, 143.0, 140.4, 134.2, 131.0, 129.4, 128.0, 127.9, 126.3, 123.3, 123.2, 122.8, 121.9, 118.8, 117.4, 113.2, 110.6, 23.9. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₄ClN₃O₂Na 374.0667; Found 374.0657.

III. Mechanism studies

1. Studies on the reversibility of C–H bond cleavage




To a reaction tube equipped with a stir bar were charged with 2-(1*H*-indol-1-yl)aniline (**1a**, 41.6 mg, 0.2 mmol), $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ (6.12 mg, 0.01 mmol), AgSbF_6 (13.7 mg, 0.04 mmol), AcOH (57 μL , 1.0 mmol), EA (2 mL) and D_2O (72 μL , 4 mmol). The tube was sealed, and the resulting mixture was stirred at $80\text{ }^\circ\text{C}$ under air for 12 h. Upon analyzing the ^1H NMR spectrum of the resulting mixture, the deuteration percentages at the α - and β -position of the indole moiety of **1a** were calculated as 77% and 62%.







To a reaction tube equipped with a stir bar were added 2-(1*H*-indol-1-yl)aniline (**1a**, 41.6 mg, 0.2 mmol), EA (2 mL), D_2O (72 μL , 4 mmol), *N*-benzyl maleimide (**2c**, 56.2 mg, 0.3 mmol), $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ (6.12 mg, 0.01 mmol), AgSbF_6 (13.7 mg, 0.04 mmol) and AcOH (57 μL , 1.0 mmol) with stirring. The mixture was stirred at $80\text{ }^\circ\text{C}$ under air for 12 h. Afterwards, it was cooled to room temperature, quenched with saturated aqueous solution of NaHCO_3 (1 mL), filtered through a pad of celite, and extracted with CH_2Cl_2 (10 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (4:1) as eluent to afford a mixture of **3u** and **3u-d_n**. Upon analyzing the ^1H NMR spectrum of the mixture, the deuteration percentages on the secondary and tertiary carbon center of the succinimide unit of **3u** were calculated to be 15% and 58%. Meanwhile, 79% deuteration on the β -position of the indole scaffold was also observed.



2. Electronic competition experiment





To a reaction tube equipped with a stir bar were added 2-(6-methoxy-1*H*-indol-1-yl)aniline (**1c**, 47.6 mg, 0.2 mmol), 2-(6-(trifluoromethyl)-1*H*-indol-1-yl)aniline (**1g**, 55.3 mg, 0.2 mmol), [Ru(*p*-cymene)Cl₂]₂ (6.12 mg, 0.01 mmol), AgSbF₆ (13.7 mg, 0.04 mmol), AcOH (57 μ L, 1.0 mmol), EA (2 mL) and *N*-methylmaleimide (**2a**, 22.2 mg, 0.2 mmol). The mixture was stirred at 80 °C under air for 12 h. Afterwards, it was cooled to room temperature, quenched with saturated aqueous solution of NaHCO₃ (1 mL), filtered through a pad of celite, and extracted with CH₂Cl₂ (10 mL \times 3). The combined organic phases were dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (4:1) as eluent to afford a mixture of **3c** and **3g**. Upon analyzing the ¹H NMR spectrum of the mixture, the ratio of **3c** to **3g** was determined to be about 1.5:1.






IV. Cell antiproliferative activity assay

Cell antiproliferative activity was evaluated by the CellTiter-Glo (Promega, USA) assay. Make 1000× compounds solution in DMSO, Add 1 μL 1000 × compounds to 49 μL growth medium to make 20 × compounds. Dilute cell suspensions in growth medium to desired density and 95 μL were taken to 96-well plate. Add 5 μL 20 × compounds into 96-well plate according to the plate map. Final DMSO concentration in each well was 0.1%. Then the cell was incubated at 37 °C, 5% CO₂ for 72 h. Equilibrate the assay plate to room temperature before measurement. Add 20 μL of CellTiter-Glo® Reagent into each well. Mix contents for 2 minutes on an orbital shaker to induce cell lysis. Incubate at room temperature for 10 minutes to stabilize luminescent signal. Record luminescence using EnVision Multilabel Reader (PerkinElmer). Cell viability (CV%) was calculated relative to vehicle (DMSO) treated control wells using following formula: Cell viability(%) = (RLU compound -RLU blank)/(RLU control-RLU blank)*100%. The IC₅₀ values were calculated using GraphPad Prism 6.0 software, fitting to a 4-parameter equation to generate concentration response curves. All assays were conducted with two parallel samples and two repetitions, and 5-fluorouracil was used as the positive control.


V. NMR spectra of 3a-3v





¹H NMR (600 MHz, CDCl₃)






¹³C{¹H} (150 MHz, CDCl₃)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)




7.481
7.466
7.310
7.298
7.286
7.273
7.257
7.039
7.037
7.026
7.023
6.866
6.873
6.856
6.842
6.831
6.829
6.816
6.812
6.802
6.798
6.498
6.488
6.406
6.403
6.394
6.391
4.085
4.085
4.079
4.074
4.070
4.065
4.058
4.050
3.733
3.729
3.712
3.425
2.951
2.943
2.936
2.921
2.896
2.909
2.896
2.872
2.863
2.854
2.846
2.824
2.815




$^1\text{H NMR}$ (600 MHz, CDCl_3)





176.901
176.088
175.790
175.694
157.058
144.781
144.521
138.790
138.395
134.641
134.545
130.528
130.503
130.459
130.284
121.822
121.755
121.364
121.310
118.957
118.679
116.682
116.285
110.767
110.736
102.329
101.675
93.813
93.773
77.275
77.063
76.853
55.701
39.263
38.999
36.435
35.890
25.099






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)






^{19}F NMR (565 MHz, CDCl_3)






$^1\text{H NMR}$ (600 MHz, CDCl_3)


7.509
7.495
7.306
7.295
7.281
7.269
7.257
7.113
7.111
7.099
7.097
7.009
6.998
6.944
6.931
6.884
6.871
6.857
6.843
6.835
6.821
6.809
6.546
6.537
4.114
4.104
4.088
4.088
4.081
4.073
4.065
4.057
3.699
3.408
2.960
2.944
2.929
2.919
2.916
2.898
2.876
2.866
2.859
2.850
2.828
2.819




176.552
175.740
175.523
175.413
144.679
144.377
138.365
137.952
136.840
136.720
130.864
130.825
130.423
130.151
128.729
126.224
126.164
121.628
121.593
121.560
121.140
119.106
118.805
116.862
116.431
110.454
110.408
102.417
101.748
77.301
77.089
76.879
39.166
38.899
36.222
35.710
25.164




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)




7.562
7.548
7.541
7.527
7.267
7.264
7.246
7.237
7.233
7.223
7.218
7.202
7.197
7.181
7.178
7.161
7.158
6.932
6.930
6.912
6.895
6.892
6.885
6.829
6.825
6.820
6.810
6.807
6.724
6.722
6.697
6.687
6.684
6.670
6.668
6.651
6.632
4.930
4.765
4.299
4.286
4.275
4.262
4.079
4.061
4.043
3.330
2.954
2.930
2.909
2.888
2.871
2.848
2.835
2.805
2.789
2.696
2.506
2.501
2.497




$^1\text{H NMR}$ (400 MHz, DMSO)




177.341
176.634
176.371
176.034
139.159
139.031
138.370
146.271
138.256
130.829
130.639
130.497
130.378
127.085
126.940
123.357
122.547
120.035
119.909
116.998
116.876
116.649
116.366
115.037
114.807
113.145
112.913
103.790
101.247
40.639
40.437
40.228
40.020
39.812
39.688
38.686
38.394
36.895
36.501
34.990
25.175
25.028




$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, DMSO)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




12 10 8 6 4 2 0 PPM




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)



200 150 100 50 0 PPM






^{19}F NMR (565 MHz, CDCl_3)

60.513
60.525







$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)










¹⁹F NMR (565 MHz, CDCl₃)

123.449
123.458
123.468
123.473
123.482
123.488
123.510
123.518
123.526
123.536
123.543
123.550









$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








¹H NMR (600 MHz, CDCl₃)






¹³C{¹H} (150 MHz, CDCl₃)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)





122.106
122.116
122.124
122.135
122.150
122.159
122.167
122.179






¹⁹F NMR (565 MHz, CDCl₃)










$^1\text{H NMR}$ (400 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)










$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)





7.616
7.601
7.594
7.490
7.485
7.404
7.399
7.383
7.366
7.360
7.256
7.191
7.173
7.165
7.155
7.138
6.972
6.966
6.951
6.934
6.785
6.763
6.756
6.734
6.578
6.559
4.124
4.110
4.100
4.087
4.074
4.063
4.050
3.780
3.457
3.092
3.066
3.042
3.019
2.995
2.973
2.953
2.942
2.930
2.896
2.883
2.858
2.845
2.812
2.799
-0.000






176.610
175.779
175.511
175.429
144.190
143.671
137.794
137.250
135.888
135.485
133.422
133.362
133.198
132.763
127.744
123.014
122.976
122.947
121.152
121.122
120.895
120.793
117.969
117.467
110.379
110.271
109.556
109.184
102.920
101.847
77.275
77.064
76.853
39.082
38.744
36.312
35.655
25.278
25.243








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








¹H NMR (400 MHz, CDCl₃)






¹³C{¹H} (100 MHz, CDCl₃)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








^1H NMR (600 MHz, CDCl_3)





^{13}C NMR (150 MHz, CDCl_3)




VI. NMR spectra of 4a-4y





^1H NMR (400 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)






^{19}F NMR (376 MHz, CDCl_3)




7.713
7.694
7.602
7.515
7.494
7.426
7.423
7.407
7.403
7.391
7.373
7.354
7.309
7.305
7.289
7.271
7.268
7.246
7.136
7.133
7.115
7.112
6.338
3.987
3.969
3.172
3.165
3.126
3.118
3.108
3.094
3.072
3.048
3.026


-0.000




¹H NMR (400 MHz, CDCl₃)





175.025
161.597
140.652
140.191
136.888
129.364
128.609
127.845
127.417
127.230
125.025
124.755
121.835
121.738
111.113
97.987
77.438
77.120
76.803
34.750
31.794
26.368






¹³C{¹H} (100 MHz, CDCl₃)










$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)






4g


$^1\text{H NMR}$ (600 MHz, CDCl_3)



4g


$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)











^{19}F NMR (565 MHz, CDCl_3)

-60.602







7.733
7.714
7.509
7.487
7.414
7.411
7.394
7.352
7.350
7.333
7.314
7.271
7.268
7.249
7.244
7.233
7.059
7.054
6.860
6.855
6.838
6.832
6.272
3.944
3.925
3.832
3.170
3.163
3.124
3.118
3.100
3.072
3.049
3.026
3.004




$^1\text{H NMR}$ (400 MHz, CDCl_3)




175.241
161.508
155.007
140.231
139.983
131.673
130.019
129.553
127.746
126.597
124.807
124.768
112.501
111.952
102.606
97.728
77.435
77.117
76.792
55.862
34.777
31.871
26.330




$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)



7.722
7.721
7.709
7.539
7.532
7.524
7.517
7.427
7.426
7.414
7.412
7.376
7.375
7.363
7.351
7.349
7.286
7.284
7.273
7.261
7.258
7.249
7.243
6.957
6.953
6.942
6.938
6.927
6.923
6.327
3.983
3.970
3.176
3.172
3.146
3.141
3.116
3.096
3.081
3.065
3.050
-0.000




$^1\text{H NMR}$ (600 MHz, CDCl_3)




10 8 6 4 2 0 PPM


175.054
161.539
159.209
157.637
141.291
140.124
133.112
129.710
129.462
129.402
127.829
126.972
124.885
124.746
111.987
111.927
110.932
110.764
105.898
105.744
97.922
97.895
77.311
77.099
76.887
34.820
31.781
26.369




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)





200 150 100 50 0 PPM






^{19}F NMR (376 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)



$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







¹H NMR (400 MHz, CDCl₃)

- 7.784
- 7.764
- 7.477
- 7.456
- 7.421
- 7.402
- 7.372
- 7.354
- 7.336
- 7.289
- 7.271
- 7.249
- 7.147
- 7.128
- 7.108
- 6.988
- 6.971
- 6.388
- 4.039
- 4.017
- 3.254
- 3.250
- 3.209
- 3.116
- 3.086
- 3.063
- 2.550


-0.000




- 175.322
- 161.655
- 140.194
- 139.311
- 136.367
- 130.410
- 130.015
- 128.682
- 127.625
- 126.775
- 125.106
- 124.756
- 122.779
- 121.367
- 108.725
- 96.427
- 77.281
- 77.069
- 76.857
- 34.808
- 31.935
- 26.343
- 18.679




¹³C{¹H} (150 MHz, CDCl₃)









-0.000




$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








^{19}F NMR (376 MHz, CDCl_3)








^1H NMR (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







^{19}F NMR (565 MHz, CDCl_3)




7.549
7.547
7.529
7.527
7.355
7.352
7.344
7.337
7.325
7.296
7.294
7.275
7.253
7.238
7.236
7.219
7.203
7.196
7.188
7.181
7.175
7.168
7.161
7.134
7.114
7.095
6.480
6.477
3.960
3.956
3.942
3.939
3.934
3.176
3.168
3.147
3.132
3.124
3.108
3.086
3.062
3.041




$^1\text{H NMR}$ (400 MHz, CDCl_3)




174.979
162.469
144.073
141.034
132.806
131.875
129.494
128.952
127.145
125.573
124.976
123.343
121.900
119.429
117.731
99.879
77.285
77.073
76.863
34.714
32.029
26.386





$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)









¹H NMR (600 MHz, CDCl₃)






-0.000





¹³C{¹H} (150 MHz, CDCl₃)








$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)




7.910
7.620
7.607
7.458
7.446
7.282
7.268
7.251
7.241
7.198
7.186
7.175
6.378

3.991
3.977
3.189
3.159
3.095
3.059


-0.000




$^1\text{H NMR}$ (600 MHz, CDCl_3)








175.034
161.924
139.637
139.317
136.414
130.963
129.814
129.210
128.993
127.616
123.115
121.580
121.079
117.133
110.843
98.746
77.318
77.106
76.895
34.794
31.878
26.374



$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)









$^1\text{H NMR}$ (600 MHz, CDCl_3)


7.775
7.762
7.632
7.618
7.420
7.407
7.391
7.352
7.340
7.326
7.273
7.261
7.250
7.238
7.231
7.220
7.214
7.201
7.183
7.170
7.158
6.381
4.873
4.850
4.755
4.731
4.012
3.998
3.210
3.206
3.179
3.176
3.098
3.083
3.068
3.052




174.999
160.828
140.118
139.930
136.618
136.007
129.891
128.975
128.819
128.500
127.848
127.742
126.720
124.936
124.781
122.624
121.140
120.938
111.110
98.082
77.288
77.076
76.857
43.484
34.815
31.906




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)




7.790
7.771
7.649
7.641
7.628
7.624
7.406
7.402
7.386
7.382
7.367
7.364
7.348
7.347
7.329
7.285
7.281
7.265
7.249
7.220
7.202
7.199
7.192
7.173
7.155
6.384
4.013
3.994
3.553
3.534
3.520
3.502
3.463
3.444
3.430
3.411
3.215
3.209
3.169
3.163
3.119
3.096
3.073
3.050
2.190
2.172
2.155
2.138
2.121
2.103
2.086
0.836
0.817
0.798




$^1\text{H NMR}$ (400 MHz, CDCl_3)





175.508
161.567
140.302
140.095
136.537
129.842
129.007
127.682
126.702
124.878
124.631
122.528
121.051
120.946
111.077
97.685
77.384
77.269
77.065
76.747
47.074
34.608
31.708
26.480
20.054
20.013






$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)








¹H NMR (600 MHz, CDCl₃)






¹³C NMR (150 MHz, CDCl₃)




VII. NMR spectra of 5a-5f





¹H NMR (400 MHz, CDCl₃)






¹³C{¹H} (100 MHz, CDCl₃)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)







$^1\text{H NMR}$ (600 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)





119.457
119.469
119.475
119.483






¹⁹F NMR (565 MHz, CDCl₃)








$^1\text{H NMR}$ (600 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)






$^1\text{H NMR}$ (600 MHz, CDCl_3)



$^{13}\text{C}\{^1\text{H}\}$ (150 MHz, CDCl_3)



VIII. X-ray crystal structure and data of 3a




Fig. S1 X-ray crystal structure of **3a** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a petroleum ether/ethyl acetate (4:1) solution of **3a**. Crystal data collection and refinement parameters of **3a** are summarized in Table S1. Intensity data were collected at 293 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. Using Olex2, the structure was solved with the SHELXS structure solution program using Direct Methods and refined with the SHELXL refinement package using Least Squares minimisation. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **3a**

Empirical formula	C ₁₉ H ₁₇ N ₃ O ₂
Formula weight	319.35
Temp, K	293(2)
Crystal system	monoclinic
Space group	P2 ₁ /n
<i>a</i> , Å	11.5596(3)
<i>b</i> , Å	10.6483(2)
<i>c</i> , Å	14.4503(3)

α (°)	90
β (°)	112.178(3)
γ (°)	90
Volume, Å ³	1647.09(7)
Z	4
d_{calc} , g cm ⁻³	1.288
λ , Å	1.54184
μ , mm ⁻¹	0.691
No. of data collected	7714
No. of unique data	3141
R_{int}	0.0223
Goodness-of-fit on F^2	1.147
R_1 , wR_2 ($I > 2\sigma(I)$)	0.0551, 0.1639
R_1 , wR_2 (all data)	0.0647, 0.1691

IX. X-ray crystal structure and data of 4a




Fig. S2 X-ray crystal structure of **4a** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a petroleum ether/ethyl acetate (4:1) solution of **4a**. Crystal data collection and refinement parameters of **4a** are summarized in Table S2. Intensity data were collected at 293 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. Using Olex2, the structure was solved with the SHELXS structure solution program using Direct Methods and refined with the SHELXL refinement package using Least Squares minimisation. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S2 Crystallographic data and structure refinement results of **4a**

Empirical formula	C ₁₉ H ₁₅ N ₃ O
Formula weight	301.34
Temp, K	293(2)
Crystal system	monoclinic
Space group	P2 ₁ /n
<i>a</i> , Å	8.6573(2)
<i>b</i> , Å	8.6388(2)
<i>c</i> , Å	19.5245(4)
α (°)	90

β (°)	96.868(2)
γ (°)	90
Volume, Å ³	1449.73(6)
Z	4
d_{calc} , g cm ⁻³	1.381
λ , Å	1.54184
μ , mm ⁻¹	0.701
No. of data collected	6282
No. of unique data	2751
R_{int}	0.0200
Goodness-of-fit on F^2	1.257
R_1 , wR_2 ($I > 2\sigma(I)$)	0.0529, 0.1427
R_1 , wR_2 (all data)	0.0668, 0.1474

X. References

1. T. U. Thikekar and C.-M. Sun, Palladium-Catalyzed Regioselective Synthesis of 1,2-Fused-Indole Diazepines via [5+2] Annulation of *o*-Indoloanilines with Alkynes, *Adv. Synth. Catal.*, **2017**, 359, 3388-3396.
2. A. Mandal, H. Sahoo, S. Dana and M. Baidya, Ruthenium(II)-Catalyzed Hydroarylation of Maleimides Using Carboxylic Acids as a Traceless Directing Group, *Org. Lett.*, **2017**, 19, 4138-4141.